On Monday, Enovis Corp (NYSE: ENOV) opened lower -9.20% from the last session, before settling in for the closing price of $29.68. Price fluctuations for ENOV have ranged from $25.47 to $49.38 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -4.65% over the past five years. Company’s average yearly earnings per share was noted 12.00% at the time writing. With a float of $56.05 million, this company’s outstanding shares have now reached $57.19 million.
Enovis Corp (ENOV) Insider Updates
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Enovis Corp is 1.99%, while institutional ownership is 114.50%. The most recent insider transaction that took place on Dec 09 ’25, was worth 27,176. In this transaction Former EVP, Strategy & Bus Dev of this company sold 999 shares at a rate of $27.20, taking the stock ownership to the 0 shares. Before that another transaction happened on Dec 09 ’25, when Company’s Former EVP, Strategy & Bus Dev sold 666 for $27.21, making the entire transaction worth $18,122. This insider now owns 160,449 shares in total.
Enovis Corp (ENOV) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 0.98 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.92) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.84% during the next five years compared to -4.65% drop over the previous five years of trading.
Enovis Corp (NYSE: ENOV) Trading Performance Indicators
Check out the current performance indicators for Enovis Corp (ENOV). In the past quarter, the stock posted a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.69. Likewise, its price to free cash flow for the trailing twelve months is 67.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -24.21, a number that is poised to hit 0.82 in the next quarter and is forecasted to reach 3.43 in one year’s time.
